Scilex Holding (SCLX) Income from Non-Controlling Interests (2020 - 2026)
Scilex Holding (SCLX) recorded quarterly Income from Non-Controlling Interests of $900000.0 in Q1 2026, down 90.91% quarter-over-quarter from $9.9 million in Q4 2025.
Scilex Holding (SCLX) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Scilex Holding's Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at $900000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed N/A year-over-year to $900000.0; the TTM figure through Mar 2026 stood at $12.3 million (changed N/A YoY), while the FY2025 annual figure was $11.8 million, changed N/A from the prior year.
- Income from Non-Controlling Interests was $900000.0 for Q1 2026 at Scilex Holding, down from $9.9 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $9.9 million in Q4 2025 to a low of $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | - |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | 9.90 Mn |
| Sep 30, 2025 | 200,000.00 |
| Mar 31, 2021 | 1.33 Mn |
| Mar 31, 2020 | -5,000.00 |